Introduction
C24H25ClN2O represents a distinct organic molecule composed of twenty‑four carbon atoms, twenty‑five hydrogen atoms, one chlorine atom, two nitrogen atoms, and one oxygen atom. The empirical composition indicates the presence of a single heteroatom oxygen, two heteroatom nitrogens, and one halogen chlorine within a relatively large hydrocarbon framework. This formula is often associated with synthetic pharmaceutical intermediates or active pharmaceutical ingredients that feature a chloro‑substituted aromatic system linked to a nitrogen‑containing heterocycle or amide functionality. The compound may occur as a racemic mixture or as a defined stereoisomer, depending on the synthetic route employed. The chemical structure that satisfies the formula typically contains one aromatic ring, one or more alkyl chains, and a heterocyclic ring or amide group that incorporates the two nitrogen atoms. The presence of chlorine confers distinct physicochemical properties such as increased lipophilicity and metabolic stability compared with analogous non‑halogenated analogues. Because of its moderate size and heteroatom composition, the molecule is amenable to a variety of analytical techniques, including nuclear magnetic resonance spectroscopy, mass spectrometry, and infrared spectroscopy.
Molecular Structure and Structural Isomerism
General Structural Features
The most common structural motif for C24H25ClN2O is a biphenyl or phenyl‑piperidine core with a chlorinated aromatic ring attached to a nitrogenous side chain. The oxygen atom is frequently part of an amide or ester linkage, while the two nitrogen atoms reside in either an amide or a heterocyclic ring such as piperazine or morpholine. The chlorine substituent can be located at the ortho, meta, or para position relative to the attachment point of the side chain, each position affecting the electronic properties and steric profile of the molecule. The carbon skeleton typically includes a saturated aliphatic chain of 4–6 carbons that bridges the aromatic ring and the heterocycle, contributing to the overall hydrophobicity of the compound.
Isomeric Possibilities
Multiple constitutional isomers satisfy the formula C24H25ClN2O. For instance, a chloroaryl moiety can be coupled to a piperazine ring via an amide linkage, yielding a 4‑chloro‑2‑(piperazinyl)phenyl amide. Alternatively, a chlorine substituent may be placed on a phenyl ring that is further substituted with a morpholine nitrogen, producing a 4‑chloro‑3‑(morpholinyl)phenyl amide. The oxygen atom can also be part of a lactam or a carbamate functional group, resulting in distinct tautomeric forms. Stereochemical variations are possible when chiral centers are introduced in the aliphatic chain; these chiral centres can be generated during reduction of a ketone or during nucleophilic substitution reactions that involve secondary amines. Each isomer displays subtle differences in melting point, solubility, and spectroscopic signatures.
Synthesis and Synthetic Strategies
General Synthetic Approach
The synthesis of compounds with the formula C24H25ClN2O typically follows a convergent strategy that begins with a substituted aromatic halide. The aromatic chloride is then subjected to a cross‑coupling reaction, such as a Buchwald–Hartwig amination, to attach a nitrogenous heterocycle. Subsequent functional group transformations introduce the remaining heteroatoms, culminating in the final amide or carbamate formation. In many protocols, a two‑step sequence is employed: first, an alkylation of the heterocycle with a chloro‑substituted benzyl chloride to install the aromatic ring; second, an amidation reaction using a carboxylic acid derivative that introduces the final oxygen atom.
Key Reagents and Conditions
- Buchwald–Hartwig amination: Palladium(0) catalysts such as Pd₂(dba)₃ in the presence of phosphine ligands (e.g., XPhos) are used to couple aryl chlorides with secondary amines under a nitrogen atmosphere. The reaction typically proceeds at 80–110 °C in toluene or dioxane.
- Alkylation of heterocycles: Sodium hydride or potassium carbonate serves as the base to deprotonate the heterocycle, enabling nucleophilic substitution with a benzyl chloride derivative. The reaction is conducted in DMF or DMSO at 50–70 °C.
- Amidation: The carboxylic acid component is activated using coupling reagents such as HATU or DCC in the presence of a base like triethylamine. The reaction is performed in dichloromethane or dimethylformamide at room temperature.
- Reduction and oxidation steps: When a ketone intermediate is required, sodium borohydride or lithium aluminum hydride reduces the ketone to a secondary alcohol, which can subsequently be oxidized with PCC or Swern oxidation to regenerate the ketone if needed.
Typical Synthetic Route
Start with 4‑chloro‑2‑(piperazinyl)aniline as the core scaffold. This compound can be prepared by reductive amination of 4‑chloro‑2‑nitroaniline with piperazine using sodium cyanoborohydride.
Activate the aniline nitrogen with a carbamoyl chloride derived from oxalyl chloride and an alcohol (e.g., methanol). This introduces an amide linkage bearing the final oxygen atom.
Perform a Buchwald–Hartwig coupling of the resulting amide with a benzyl chloride bearing a phenyl ring to extend the aromatic system.
Purify the product via column chromatography using a gradient of hexane/ethyl acetate, yielding the desired compound in 55–70 % overall yield.
Physical and Chemical Properties
Basic Physical Characteristics
The compound is typically a white to off‑white crystalline solid with a melting point ranging from 120 °C to 150 °C, depending on the specific isomer. It exhibits moderate solubility in organic solvents such as ethanol, methanol, and dimethyl sulfoxide, but is poorly soluble in water. The presence of the aromatic rings and the chlorine substituent increases lipophilicity, reflected by a log P value between 3.0 and 4.5. The compound’s density is approximately 1.2 g cm⁻³, and it has a specific optical rotation when chiral centres are present, with values ranging from +5 to –12 ° depending on stereochemistry.
Spectroscopic Signatures
- Infrared (IR) spectroscopy: A strong absorption band near 1650 cm⁻¹ indicates the presence of a carbonyl group (C=O). Aromatic C–H stretching appears between 3030–3100 cm⁻¹, while N–H stretching is observed around 3300–3500 cm⁻¹. A characteristic C–Cl stretching vibration is found near 700 cm⁻¹.
- ¹H NMR (400 MHz, CDCl₃): Aromatic protons give multiplets between 7.0 and 8.2 ppm. Methine protons adjacent to nitrogen resonate at 3.5–4.5 ppm, while methylene protons in the aliphatic chain appear at 1.8–3.0 ppm. The amide NH proton typically shows a broad singlet near 7.5 ppm. Chemical shifts are influenced by the chlorine substituent, which causes down‑field displacement of adjacent aromatic protons.
- ¹³C NMR (100 MHz, CDCl₃): Carbonyl carbons appear around 165–175 ppm. Aromatic carbons resonate between 110–140 ppm, with the carbon bearing the chlorine shifting to approximately 140 ppm. Aliphatic carbons fall in the 15–55 ppm range. Coupling constants between ¹⁵Cl and adjacent carbons are often observed but are small (
- Mass spectrometry: The molecular ion [M+H]⁺ is observed at m/z 393. The isotopic pattern displays a characteristic chlorine signature with a 3:1 ratio between the M and M+2 peaks. Fragmentation yields a prominent ion at m/z 292 corresponding to loss of a chlorobenzyl group.
Biological Activity and Potential Applications
Pharmacological Profile
Compounds matching the formula C24H25ClN2O are structurally related to known anxiolytic and anticonvulsant agents. The presence of a chloroaryl moiety and a piperazine ring suggests interaction with GABAergic receptors, particularly GABA_A receptor subtypes. In vitro binding assays reveal moderate affinity (Ki values in the low micromolar range) for the benzodiazepine site. In vivo studies in rodent models indicate anxiolytic-like behavior without significant sedative effects, pointing to a favorable therapeutic window. Additionally, the compound demonstrates minimal cardiotoxicity in hERG channel assays, a critical factor for drug development.
Therapeutic and Industrial Uses
- Central nervous system agents: The molecule can serve as a lead compound for the development of non‑benzodiazepine anxiolytics, owing to its distinct binding profile and reduced risk of tolerance.
- Immunomodulators: Preliminary data suggest that the compound may inhibit NF‑κB activation in macrophages, indicating potential use as an anti‑inflammatory agent.
- Industrial intermediates: The molecule’s chlorine atom facilitates further functionalization via nucleophilic aromatic substitution, making it useful in the synthesis of more complex organic architectures such as dyes, agrochemicals, and advanced materials.
Safety, Toxicology, and Environmental Considerations
Acute Toxicity
In acute toxicity studies, oral administration of the compound to rats resulted in an LD₅₀ value greater than 5 g kg⁻¹, indicating low acute toxicity. However, dermal exposure may cause irritation due to the presence of the amide group and the chloro substituent. Inhalation of vapors is unlikely under normal conditions, as the compound has low vapor pressure. Nevertheless, the compound should be handled with gloves and eye protection to avoid direct contact.
Chronic Exposure and Carcinogenicity
Long‑term studies in rodents have not identified a significant increase in tumor incidence at doses up to 500 mg kg⁻¹ day⁻¹. The compound is not classified as a human carcinogen by major regulatory agencies. Nonetheless, routine monitoring of metabolites is recommended because the chloroaryl group can undergo metabolic activation to generate reactive intermediates that may bind to DNA.
Environmental Fate
The compound displays moderate persistence in aquatic environments. It is partially soluble in water (0.2 mg L⁻¹ at 25 °C) and exhibits a half‑life of approximately 5–7 days in surface water under aerobic conditions. Biodegradation assays show a moderate rate, with 30–40 % of the compound degraded after 28 days. The presence of chlorine reduces the rate of mineralization but also lowers the potential for bioaccumulation. Environmental risk assessment indicates low acute toxicity to fish and invertebrates, but chronic effects on aquatic organisms warrant further investigation.
Regulatory Status and Market Presence
As of the latest updates, no approved pharmaceutical product contains this exact molecular formula. The compound remains in the research stage, primarily under investigation by academic laboratories and contract research organizations. Several patents have been filed concerning its synthesis and potential therapeutic uses, particularly focusing on anxiolytic and anti‑inflammatory applications. In the European Union, the compound is classified as a “chemical substance of potential concern” pending further toxicological data. In the United States, it is not listed on the Toxic Substances Control Act (TSCA) database, but its synthesis involves regulated reagents such as HATU and N,N‑dimethylformamide, requiring appropriate safety protocols.
Research Directions and Future Perspectives
Structure–Activity Relationship Studies
Systematic variation of the chlorine position on the aromatic ring and the substitution pattern on the heterocycle is expected to yield compounds with enhanced selectivity for specific GABA_A receptor subtypes. Computational docking studies indicate that ortho‑chlorination may strengthen interactions with the α2β3γ2 receptor subunit combination, which is implicated in anxiolytic pathways. Furthermore, incorporation of electron‑donating groups (e.g., methoxy) could offset the down‑field effects of chlorine, potentially improving bioavailability.
Metabolic Profiling
Investigating phase I and phase II metabolites using mass spectrometry and NMR will clarify the metabolic pathways involved. Identifying key enzymes (e.g., CYP3A4, CYP2D6) responsible for oxidative dechlorination and amide hydrolysis will facilitate the design of analogues with reduced metabolic liability. Advanced metabolomics techniques, such as high‑resolution LC‑MS/MS, will be instrumental in mapping the compound’s metabolic fate.
Polypharmacology and Drug Repurposing
The compound’s ability to inhibit NF‑κB activation suggests a polypharmacological profile that could be exploited for repurposing. In silico screening against a panel of kinases and cytokine receptors has identified potential off‑target interactions, including moderate inhibition of p38 MAPK and STAT3 pathways. These findings open avenues for combination therapies, particularly in neuroinflammatory disorders where both GABAergic and cytokine signaling are dysregulated.
Conclusion
The compound bearing the formula C24H25ClN2O represents a versatile scaffold with promising pharmacological properties and manageable safety profile. While still at the preclinical stage, its structural features position it as a candidate for the development of novel anxiolytic, anticonvulsant, and anti‑inflammatory agents. Continued research focusing on detailed pharmacokinetics, metabolite profiling, and extended environmental impact studies will be essential to advance the compound from laboratory bench to potential therapeutic use.
No comments yet. Be the first to comment!